Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Follow-Up Questions
Quel est le ratio P/E de Psyence Biomedical Ltd (PBM) ?
Le ratio P/E de Psyence Biomedical Ltd est de 2.6223
Qui est le CEO de Psyence Biomedical Ltd ?
Mr. Marc Balkin est le Chief Executive Officer de Psyence Biomedical Ltd, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action PBM ?
Le prix actuel de PBM est de $5.18, il a decreased de 2.16% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Psyence Biomedical Ltd ?
Psyence Biomedical Ltd appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Psyence Biomedical Ltd ?
La capitalisation boursière actuelle de Psyence Biomedical Ltd est de $3.6M
